Gerhard Gründer
Prof. Dr., Head of Department of Molecular Neuroimaging at the Central Institute of Mental Health (Mannheim)
Data updated
Research Footprint
Gerhard Gründer appears in 8 tracked papers (2020–2026) and 1 clinical trial, most studied alongside Psilocybin, Placebo and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance (184 citations).
Frequent co-authors: Henrik Jungaberle, Lea Mertens and Max Wolff.
Background & Research
Gerhard Gründer is a psychiatrist and professor at the Central Institute of Mental Health in Mannheim, where he heads the Department of Molecular Neuroimaging. His research focuses on the neurobiology and clinical effects of psychotropic substances, especially psilocybin and other psychedelic compounds, and he has led or coauthored major publications on psychedelic therapy, including the EPIsoDE program.
Key Impact
He is a leading clinical researcher on psilocybin for treatment-resistant depression and a prominent contributor to the implementation of psychedelic therapies in European psychiatric care.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Gerhard Gründer is associated with.